摘要
目的:研究表明最小干扰对轻度阿尔茨海默病(AD)患者的项目记忆有良好的影响。我们进行了一项研究,以测试这些有益的影响是否延伸到源头。 记忆,即记忆以前获得信息的情景的能力。 方法:26名轻度AD参与者和28名对照者操纵6个对象或观察实验者操纵其他6个对象。立即召回物品后(什么是商品?)和苏。 RCE召回(以前是由谁操纵的),干扰或最小干扰条件被管理。在干扰情况下,参与者使用neu进行评估。 心理测试10分钟。在最小干扰的情况下,他们独自在一个黑暗和安静的房间休息10分钟。同时遵循干扰和最小干扰条件。 通过延迟回忆,参与者被要求记住先前呈现的对象及其来源。 结果:轻度干扰组的项目记忆高于AD组(p<.01)和对照组(p<.01)。此外,AD参与者展示了更高的项目。 即刻回忆时的记忆比后续干扰(p<.001)或最小干扰(p<.001);控制组在立即回忆时的项目记忆也比后续干扰更高(p<.001)。 .001)或最小干扰(p<.001)。考虑到源记忆,AD参与者(p>1)和对照组(p>1)在干扰和最小干扰后有相似的源记忆(P>0.05)。 1)此外,AD参与者在立即回忆时比干扰(p<.001)或最小干扰(p<.001)表现出更高的源记忆;对照组也显示出更高的源备忘录 立即回忆比跟随干扰(p<.001)或最小干扰(p<.001)。 结论:AD患者海马依赖的联想或巩固过程的失败可能排除了对源记忆干扰最小的好处。然而,AD患者可能会显示出一些Capa。 城市要保留简单的材料,如果材料呈现后有短时间的延迟,就没有进一步的刺激。
关键词: 阿尔茨海默病,海马,记忆康复,最小干扰,源记忆。
Current Alzheimer Research
Title:Beneficial effect of minimal interference on item memory but not on source memory in Alzheimer's disease
Volume: 15 Issue: 11
关键词: 阿尔茨海默病,海马,记忆康复,最小干扰,源记忆。
摘要: Objectives: Research suggests beneficial effects of minimal interference on item memory in mild Alzheimer’s disease (AD). We conducted a study to test whether these beneficial effects extend to source memory, i.e., the ability to remember the episodic context in which an information was previously acquired.
Method: Twenty-six mild AD participants and 28 controls manipulated six objects or watched the experimenter manipulating six other objects. After immediate item recall (“what were the items?”) and source recall (“by whom the items were previously manipulated?”), an interference or a minimal interference condition was administrated. In the interference condition, participants were assessed with neuropsychological tests for 10 min. In the minimal interference condition, they rested alone in a dark and quiet room for 10 minutes. Both interference and minimal interference conditions were followed by the delayed recall, on which participants were asked to remember the previously-presented objects and their source.
Results: Higher item memory was observed following minimal interference than following interference in AD participants (p < .01) and controls (p < .01). Also, AD participants demonstrated higher item memory on immediate recall than following interference (p < .001) or minimal interference (p < .001); controls also demonstrated higher item memory on immediate recall than following interference (p < .001) or minimal interference (p < .001). Considering source memory, similar source memory was observed following interference and minimal interference in AD participants (p > .1) and controls (p > .1). Also, AD participants demonstrated higher source memory on immediate recall than following interference (p < .001) or minimal interference (p < .001); controls also demonstrated higher source memory on immediate recall than following interference (p < .001) or minimal interference (p < .001).
Conclusion: Failures of hippocampus-dependent associative or consolidation processes in AD may preclude benefits of minimal interference for source memory. Nevertheless, AD patients may show some capacity to retain simple material, should the material presentation be followed by short delays that are free of further stimuli.
Export Options
About this article
Cite this article as:
Beneficial effect of minimal interference on item memory but not on source memory in Alzheimer's disease, Current Alzheimer Research 2018; 15 (11) . https://dx.doi.org/10.2174/1567205015666180711105242
DOI https://dx.doi.org/10.2174/1567205015666180711105242 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Schizophrenia: Redox Regulation and Volume Neurotransmission
Current Neuropharmacology MAP Kinase Pathways in Neuronal Cell Death
CNS & Neurological Disorders - Drug Targets Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Microendophenotypes of Psychiatric Disorders: Phenotypes of Psychiatric Disorders at the Level of Molecular Dynamics, Synapses, Neurons, and Neural Circuits
Current Molecular Medicine Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Polycystic Ovary Syndrome and Infertility: From Molecular Perspective
Current Women`s Health Reviews Pollutants in Organic Chemistry and Medicinal Chemistry Education Laboratory. Experimental and Machine Learning Studies
Current Topics in Medicinal Chemistry Clinical Applications of Pinhole Single Photon Emission Tomography
Current Medical Imaging Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Galantamine-based Hybrid Molecules with Acetylcholinesterase, Butyrylcholinesterase and γ-Secretase Inhibition Activities
Current Alzheimer Research Genetics of Cholesterol and Lipoprotein Metabolism
Recent Patents on Cardiovascular Drug Discovery In Silico and In Vitro: Identifying New Drugs
Current Drug Targets Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy Contemporary Anticholinesterase Pharmaceuticals of Natural Origin and Their Synthetic Analogues for the Treatment of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase
Current Topics in Medicinal Chemistry Gene Mining and Functional Genomics in Human Osteoarthritis
Current Genomics Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews